Access to Kidney Transplant of Obese Patients Beginning Dialysis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire, Amiens
About this trial
Obesity is in constant increase all over the world and affects 35% of the global population according to the World Health Organisation. It is associated with other cardiovascular risk factors (particularly hypertension and diabetes) and with high morbi-mortality. It is also responsible for an increase of the risk of developing chronic kidney diseases (CKD). In fact, obese patients represent 25% of the dialysis population and Picardy is one of the most affected areas. However, their access to kidney transplant is still restricted and the reasons are not completely understood.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age over 18 years old.
Patients with BMI≥30 kg/m2 (for study population) and 25≤BMI≤30 kg/m2(for control population) one month after dialysis initiation.
Patients agree with their data collection.
Disqualifiers
Patients with bariatric surgery history.
Patients needed dialysis for graft dysfunction.
Data loss.
Trial population
Patients will be included in the study one month after the dialysis initiation. All clinical (obesity history, comorbidities, nephropathy aetiology and treatment…) and biological (nutrition markers, hemoglobin, brain natriuretic peptide (BNP)…) informations after one month and during the two years of follow-up (weight evolution, obesity complications, transplant path...) will be collected.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
100 Participants
are grouped into 2 trial groupsGroup A: patients with BMI≥30 kg/m2
Group B: patients with 25≤BMI≤30 kg/m2
Trial outcomes
Primary outcomes
1
variation of pre-transplant status two years after the obese patients' dialysis initiation between both groups
Time frame
two yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov